Mood Stabilizers and the Influence on Global Leukocyte DNA Methylation in Bipolar Disorder.
Mood Stabilizers and the Influence on Global Leukocyte DNA Methylation in Bipolar Disorder.
复制标题
DOI：
10.1159/000430867
复制
发表时间：
2015-07-01
期刊：
影响因子：
--
通讯作者：
Lavebratt, Catharina
中科院分区：
文献类型：
--
作者：
Backlund, Lena;Wei, Ya Bin;Lavebratt, Catharina
关于双相情感障碍（BD）的治疗、治疗反应和DNA甲基化状态之间的关系知之甚少。我们调查了在不同治疗下，健康对照组和双相情感障碍患者之间的整体DNA甲基化水平是否存在差异。在接受锂单药治疗（n = 29）或联合治疗（n = 32）的双相情感障碍患者和健康对照（n = 26）的白细胞DNA中测量了总体DNA甲基化。使用Alda量表评估锂反应。锂单药治疗与低甲基化相关（F = 4.63，p = 0.036）。与锂单药治疗相比，锂+丙戊酸盐显示了高甲基化模式（F = 7.27，p = 0.011）。锂反应与DNA甲基化水平无关。这些数据表明，BD的治疗选择可能导致不同水平的整体DNA甲基化。然而，需要进一步的研究来了解其临床意义。
Little is known about the relationship between treatments for bipolar disorder (BD), their therapeutic responses and the DNA methylation status. We investigated whether global DNA methylation levels differ between healthy controls and bipolar patients under different treatments. Global DNA methylation was measured in leukocyte DNA from bipolar patients under lithium monotherapy (n = 29) or combination therapy (n = 32) and from healthy controls (n = 26). Lithium response was assessed using the Alda scale. Lithium in monotherapy was associated with hypomethylation (F = 4.63, p = 0.036). Lithium + valproate showed a hypermethylated pattern compared to lithium alone (F = 7.27, p = 0.011). Lithium response was not associated with DNA methylation levels. These data suggest that the choice of treatment in BD may lead to different levels of global DNA methylation. However, further research is needed to understand its clinical significance.